Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SRP2151

Sigma-Aldrich

HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 from hepatitis C virus

recombinant, expressed in E. coli, ≥80% (SDS-PAGE)

Synonyme(s) :

Hepatitis C virus NS3 protease, NS3, NS4ANS3 complex, pfam02907

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352204
Nomenclature NACRES :
NA.26

Source biologique

hepatitis C virus

Produit recombinant

expressed in E. coli

Pureté

≥80% (SDS-PAGE)

Forme

frozen liquid

Poids mol.

~22.7 kDa

Conditionnement

pkg of 10 μg

Concentration

500 μg/mL

Couleur

colorless to clear

Numéro d'accès NCBI

X61596

Conditions d'expédition

dry ice

Température de stockage

−70°C

Informations sur le gène

hepatitis C virus ... HCVgp1(951475)

Actions biochimiques/physiologiques

Persistent infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV is an enveloped, single-stranded RNA virus with a 9.6-kb positive-polarity genome, which encodes a polyprotein precursor of about 3,000 amino acids. The HCV polyprotein is proteolytically processed by cellular and HCV proteases into at least 10 distinct products. NS3 serine protease and helicase as well as NS5B RNA-dependent RNA polymerase are believed to be components of a replication complex responsible for viral RNA replication and have been shown to be essential for the HCV replication in chimpanzees. These HCV enzymes have been the major targets for the development of HCV-specific therapeutics during the past decade. The HCV NS3/4A protease is responsible for cleavage at four sites within the HCV polyprotein to generate the N termini of the NS4A, NS4B, NS5A, and NS5B proteins. It has been shown that the central region (amino acids 21-30) of the 54-residue NS4A protein is essential and sufficient for the enhancement of proteolytic activity of the NS3 serine protease. In recent phase I trials, a 2-3-log reduction of HCV viral load was observed after a 2-day treatment with a serine protease inhibitor, which provided the first proof-of-concept evidence that HCV NS3/4A protease inhibitors could be a new therapeutic option for hepatitis C patients.

Forme physique

Clear and colorless frozen liquid solution

Notes préparatoires

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Blight, K. J., et al.
Antiviral Ther., 3, 71-81 (1998)
M J Alter
Hepatology (Baltimore, Md.), 26(3 Suppl 1), 62S-65S (1997-09-26)
In the United States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined from an estimated 180,000 in the mid 1980s to an estimated 28,000 in 1995. Approximately 25% to 30% of these infections are
A A Kolykhalov et al.
Journal of virology, 74(4), 2046-2051 (2000-01-22)
Hepatitis C virus (HCV) infection is a widespread major human health concern. Significant obstacles in the study of this virus include the absence of a reliable tissue culture system and a small-animal model. Recently, we constructed full-length HCV cDNA clones

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique